Copyright
©The Author(s) 2025.
World J Clin Oncol. Nov 24, 2025; 16(11): 110911
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.110911
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.110911
Figure 1 Pharmacokinetic profile of cardamonin.
1Indicates factors that impede oral bioavailability. CYP 1A2: Cytochrome P450 1A2; CYP 2E1: Cytochrome P450 2E1.
Figure 2 Graphical representation of structure-activity relationship of cardamonin and its analogues.
A: Chalcone molecule; B: Cardamonin molecule; C: Copper Cardamonin dimer.
- Citation: Badroon NA, Alsalahi A, Aljaberi MA, Abdul Majid N, Alshawsh MA. Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications. World J Clin Oncol 2025; 16(11): 110911
- URL: https://www.wjgnet.com/2218-4333/full/v16/i11/110911.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i11.110911
